|
|
Post by sportsrancho on Jun 3, 2017 19:54:06 GMT -5
I don't think MannKind will accept a BO from a company unless they are Mann affiliated. I can't think of one BP that shares the same ideals that Al Mann did or as MannKind currently does. Not sure that matters anymore. In case you missed it, Mannkind recently kicked Al's friend, protege, and golden boy, Matt Pfeffer, to the curb. By the way, I'm just curious. Al Mann died in February 2016. Mike Castagna joined Mannkind in March of 2016. He was recruited by Matt, not Al. So did Al Mann and Mike Castagna every actually meet? Anyone know? Very good question:-) I can't be positive but I believe they did. Mike speaks highly of him. |
|
|
|
Post by golfeveryday on Jun 3, 2017 20:01:18 GMT -5
$10 is 1 billion MC. I think $6-10 is about right currently. I'm not sure if I'm one of your faves but I'll take a deal in July for $1 billion! I think most would. You know you are sax! From way back:-) I'm thinking BO in late 2018 for at least 2-3b 30pps. But it all depends on the tipping point and how fast it comes. On the price and the time of BO. If we get to late 2018 promoting alone then it is because we are growing and $30 is way more than achievable. |
|
|
|
Post by agedhippie on Jun 3, 2017 21:00:51 GMT -5
In the useless facts section - the symbol for MiniMed was MNMD, one letter different from MNKD.
|
|
|
|
Post by mango on Jun 4, 2017 4:22:00 GMT -5
I don't think MannKind will accept a BO from a company unless they are Mann affiliated. I can't think of one BP that shares the same ideals that Al Mann did or as MannKind currently does. Not sure that matters anymore. In case you missed it, Mannkind recently kicked Al's friend, protege, and golden boy, Matt Pfeffer, to the curb. By the way, I'm just curious. Al Mann died in February 2016. Mike Castagna joined Mannkind in March of 2016. He was recruited by Matt, not Al. So did Al Mann and Mike Castagna every actually meet? Anyone know? Isn't Matt P. around retirement age? Perhaps the dual role of CEO and CFO while facilatating a successful and complete transformation of company was the high note he preferred to end on? I know I would. He was on the BoD and obviously highly respected by Kent Kresa. If you think KK had nothing to do with the strategic developments of MannKind during 2016 then you have not done your basic DD. The man is known for and renowned for this exact thing. Read carefully these two quotes by Kent Kresa just a few months more than a year apart: • "Effectively prepared Michael to be his successor." • "Built the capabilities from the bottom -up necessary" There is no reading between the lines. The truth is printed right there for anyone to read. The words Matt, effectively, prepared, Castagna, to, be, his, and successor (assuming you know what the words mean) says it all. To help with this incase that is not easy enough for you: The words, built, the capabilities, and from the bottom-up should only be a bellringer that this is KK work. Anyways, you were saying? |
|
|
|
Post by matt on Jun 4, 2017 6:55:06 GMT -5
Could not disagree more.....the price will be paid i.e., $10B+. You first have to find a pharma company willing to pay that amount. Valuations have been crazy in pharma before, the late 1980's saw a lot of recombinant proteins sold for multi-billion dollar price tags, and again with some small molecules in the late 1990's when the dot-com bubble overheated the market. The pharmas spent much of the last fifteen years writing off those crazy bets as they downsized their operations. There are always two parts to an buyout and longs tend to ignore the second part; there must be a management team on the acquirer's side willing to risk their careers paying above the odds for a new drug. Every big pharma has vocal shareholders, often large institutions, active analyst coverage, a more sophisticated and experienced board that MNKD has, and an investment bank that has to write a fairness opinion. A lot of stars have to align to get a valuation in the $10B range and Afrezza is probably from the wrong galaxy. |
|
|
|
Post by peppy on Jun 4, 2017 7:08:09 GMT -5
Could not disagree more.....the price will be paid i.e., $10B+. You first have to find a pharma company willing to pay that amount. Valuations have been crazy in pharma before, the late 1980's saw a lot of recombinant proteins sold for multi-billion dollar price tags, and again with some small molecules in the late 1990's when the dot-com bubble overheated the market. The pharmas spent much of the last fifteen years writing off those crazy bets as they downsized their operations. There are always two parts to an buyout and longs tend to ignore the second part; there must be a management team on the acquirer's side willing to risk their careers paying above the odds for a new drug. Every big pharma has vocal shareholders, often large institutions, active analyst coverage, a more sophisticated and experienced board that MNKD has, and an investment bank that has to write a fairness opinion. A lot of stars have to align to get a valuation in the $10B range and Afrezza is probably from the wrong galaxy. I am surprised by this reply. I was anticipating, a two word reply. August bankruptcy. Heh.
|
|
|
|
Post by deaner3 on Jun 4, 2017 7:16:14 GMT -5
Times are changing.
The bashers arguments used to be bankruptcy, now it seems to be you aren't going to make as much long term as you think you are. The StockTwits side went from having annoying but having a point to now they just do name calling since they don't have anything else
Times, they are a changing. Exciting few months ahead for mannkind longs.
|
|
|
|
Post by scander on Jun 4, 2017 7:38:17 GMT -5
Could not disagree more.....the price will be paid i.e., $10B+. You first have to find a pharma company willing to pay that amount. Valuations have been crazy in pharma before, the late 1980's saw a lot of recombinant proteins sold for multi-billion dollar price tags, and again with some small molecules in the late 1990's when the dot-com bubble overheated the market. The pharmas spent much of the last fifteen years writing off those crazy bets as they downsized their operations. There are always two parts to an buyout and longs tend to ignore the second part; there must be a management team on the acquirer's side willing to risk their careers paying above the odds for a new drug. Every big pharma has vocal shareholders, often large institutions, active analyst coverage, a more sophisticated and experienced board that MNKD has, and an investment bank that has to write a fairness opinion. A lot of stars have to align to get a valuation in the $10B range and Afrezza is probably from the wrong galaxy. It would have been easier if there were forward thinking board members in those pharmaceutical companies as forward thinking as some posters here. 😜 Who would value companies in thoughts and not numbers as finally it has go through financing department |
|
|
|
Post by mnkdfann on Jun 4, 2017 10:15:00 GMT -5
Not sure that matters anymore. In case you missed it, Mannkind recently kicked Al's friend, protege, and golden boy, Matt Pfeffer, to the curb. By the way, I'm just curious. Al Mann died in February 2016. Mike Castagna joined Mannkind in March of 2016. He was recruited by Matt, not Al. So did Al Mann and Mike Castagna every actually meet? Anyone know? Isn't Matt P. around retirement age? Perhaps the dual role of CEO and CFO while facilatating a successful and complete transformation of company was the high note he preferred to end on? I know I would. He was on the BoD and obviously highly respected by Kent Kresa. Matt is 59 according to an online bio for him, a little early for retirement unless he has some health issues or something. Fair points about Kresa though. |
|
|
|
Post by sophie on Jun 4, 2017 14:02:27 GMT -5
Even more bizarre to me is a man who many on here believe turned the tide only to jump ship once it came time to enjoy the fruits of his labor. I don't know what to make of Matt leaving. I can't make it a positive in my mind no matter how I look at it.
|
|
|
|
Post by mango on Jun 4, 2017 14:54:23 GMT -5
Isn't Matt P. around retirement age? Perhaps the dual role of CEO and CFO while facilatating a successful and complete transformation of company was the high note he preferred to end on? I know I would. He was on the BoD and obviously highly respected by Kent Kresa. Matt is 59 according to an online bio for him, a little early for retirement unless he has some health issues or something. Fair points about Kresa though. James S. Shannon , M.D., MRCP (UK) rejoined our board in May 2015 after previously serving as a director from February 2010 until April 2012. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. James S. Shannon is currently 60 years old. Matthew Pfeffer also still serves on the BoD for Second Sight. |
|
|
|
Post by peppy on Jun 4, 2017 15:57:17 GMT -5
Even more bizarre to me is a man who many on here believe turned the tide only to jump ship once it came time to enjoy the fruits of his labor. I don't know what to make of Matt leaving. I can't make it a positive in my mind no matter how I look at it. Thinking it all over Sophie, as people on the board pointed it, a problem may have happened between Matt P and the board over Aegis?
|
|
|
|
Post by sophie on Jun 4, 2017 16:40:00 GMT -5
That's certainly a possibility. That's still a negative in my mind.
For someone like Matt who has given so much time and effort to MNKD to be kicked to the curb over that blunder means the board thinks it must have been severe enough of a mistake to terminate him for it. If that's truly the case, I wonder why Matt didn't discuss this plan with the board before proceeding. Matt has had his share of soundbyte missteps, but he always struck me as a careful and meticulous person who didn't shoot from the hip. If he was fired, I can't imagine it was just over Aegis. He could have been demoted to just CFO.
Whatever the case, you've got one less person who shares Al's vision on the team and one less person with experience with technosphere, Afrezza, and all things MNKD. They're also going to have to try to find another CFO to take his place and rely on Rose while all these new deals and hopefully new revenues will be coming in.
I've left room for this to end up being a net positive in my mind if they make the right hire to replace Matt and if Mike has been the brainchild thus far behind all the operations/deals anyway but has been held back by Matt. While that certainly may be the case- none of us really know who has contributed what thus far- I think Mike has been given a lot of credit on here based on what he did at AMGEN. I don't think he has produced as much as even he expected to this point. Maybe I'm wrong. I suspect I'm not when we've heard since July that Mike's crew was going to help fix the script count. While the trend is improving, this was promised almost a year ago.
The departure of Matt is an ominous sign to me. For a guy like Matt, who stated over and over that he was passionately and wholeheartedly committed to making sure Al Mann's vision became reality, to step aside at this juncture (except for health issues) is mind-boggling to me. Unless he suddenly grew a distaste for wealth or had a sudden change of heart and now wants to destroy anything related to Al Mann, his departure is not a good thing. Resuming the role of CFO wouldn't have been as much cause for alarm for me. Leaving entirely means he was canned, believes MNKD is now unsalvageable, or was forced to for health reasons. If for health reasons, I think the board could have easily addressed that in their public statement.
As far as the buyout rumors based on Matt's departure, no business today operates on a handshake. There is no way that MNKD would replace Matt with Mike on a verbal deal that in doing so AMGEN or any other corporation would buy them under those terms. There would be no need as it accomplishes nothing. If AMGEN wanted to acquire MNKD, they could do the same thing as soon as they sign the contract. At that point, it's their business to do with as they see fit. To be led to believe otherwise is disingenuous or foolish.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 4, 2017 22:57:17 GMT -5
Times are changing. The bashers arguments used to be bankruptcy, now it seems to be you aren't going to make as much long term as you think you are. The StockTwits side went from having annoying but having a point to now they just do name calling since they don't have anything else Times, they are a changing. Exciting few months ahead for mannkind longs. Agreed. If and when rx numbers climb why sell. Japan, China, the rest of world will want this. I will not let go of my shares for less than $100 each. Underwater I am. A TRUE believer I be. Bring it haters. I love to use OLED as an example. So much disbelief in the beginning. Shorts, haters, and more shorts o my. Where does OLED sit at now? Holy cow poo. Never say never. $100+. Damn. |
|
|
|
Post by straightly on Jun 5, 2017 0:40:25 GMT -5
Times are changing. The bashers arguments used to be bankruptcy, now it seems to be you aren't going to make as much long term as you think you are. The StockTwits side went from having annoying but having a point to now they just do name calling since they don't have anything else Times, they are a changing. Exciting few months ahead for mannkind longs. Agreed. If and when rx numbers climb why sell. Japan, China, the rest of world will want this. I will not let go of my shares for less than $100 each. Underwater I am. A TRUE believer I be. Bring it haters. I love to use OLED as an example. So much disbelief in the beginning. Shorts, haters, and more shorts o my. Where does OLED sit at now? Holy cow poo. Never say never. $100+. Damn. "If and when rx numbers climb", indeed! If they do indeed! I wonder if Mike know they do not? |
|
